CD274 and neoplasm: A significant improvement in DFS was shown for the immunotherapy arm (57.4 versus 40.8 months, HR 0.83, 95% CI 0.69–1.00), as well as a preliminary trend for improved OS, especially driven by the subgroup with tumours with PD-L1 tumor proportion score (TPS) of 50% or higher (HR 0.48 for DFS, 95% CI 0.32–0.72; HR 0.47 for OS, 95% CI 0.28–0.77) [10, 11].